Orchestra BioMed Holdings, Inc./$OBIO
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Orchestra BioMed Holdings, Inc.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.
- Ticker
- $OBIO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 86
- Headquarters
- New Hope, United States
- Website
- www.orchestrabiomed.com
OBIO Metrics
BasicAdvanced
$473M
-
-$0.92
0.55
-
Price and volume
Market cap
$473M
Beta
0.55
52-week high
$6.50
52-week low
$3.46
Average daily volume
399K
Financial strength
Current ratio
7.251
Quick ratio
7.166
Long term debt to equity
3.879
Total debt to equity
3.923
Interest coverage (TTM)
-9.31%
Profitability
EBITDA (TTM)
-60.605
Gross margin (TTM)
99.56%
Net profit margin (TTM)
-182.50%
Operating margin (TTM)
-195.39%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
-35.86%
Return on equity (TTM)
-182.29%
Valuation
Price to revenue (TTM)
12.188
Price to book
47.46
Price to tangible book (TTM)
47.46
Price to free cash flow (TTM)
-5.927
Free cash flow yield (TTM)
-16.87%
Free cash flow per share (TTM)
-1.014
Growth
Revenue change (TTM)
1,007.38%
Earnings per share change (TTM)
-48.71%
3-year revenue growth (CAGR)
105.40%
3-year earnings per share growth (CAGR)
-16.09%
What the Analysts think about OBIO
Analyst ratings (Buy, Hold, Sell) for Orchestra BioMed Holdings, Inc. stock.
Analyst projections of the future price of Orchestra BioMed Holdings, Inc. stock.
Bulls say / Bears say
The AVIM pivotal trial has completed enrolment with 349 patients, above its target, bringing a key data catalyst closer. Medtronic plans to seek FDA clearance if results are positive and would provide an established route to market. (GlobeNewswire)
Virtue SAB offers a second potential value driver: its small pilot study reported positive three-year clinical data, and the company is advancing a US pivotal trial against a marketed rival balloon. Success could broaden the business beyond AVIM. (GlobeNewswire)
The November equity raise added $80.5 million to $101.9 million of cash and marketable securities at quarter-end, which the company says funds operations through 2028. That gives it more scope to reach major trial milestones without an immediate need to raise cash again. (GlobeNewswire)
AVIM remains a high-stakes clinical bet: pivotal results are expected in 2027, and Medtronic's planned regulatory filing depends on positive results. If the trial misses its efficacy or safety targets, the main near-term growth case could weaken sharply. (GlobeNewswire)
Virtue still needs to prove itself in a large head-to-head trial of about 740 patients against Boston Scientific's AGENT balloon, with enrolment only targeted to finish by the end of 2027. That leaves a long clinical and regulatory path before it can generate commercial sales. (GlobeNewswire)
The $80.5 million raise came from issuing 17.25 million common shares at $5 each, increasing the share count and diluting existing holders. Future fundraising could still be needed if trial costs or timelines exceed current plans. (GlobeNewswire, StreetInsider)
Data summarised monthly by Lightyear AI. Last updated on 11 Nov 2026.
OBIO Financial Performance
Revenues and expenses
OBIO Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing OBIO
Fund name | Fund size | $OBIO weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 0.02% |
iShares Nasdaq US Biotechnology$BTEC | $1.3B | 0.02% |
SPDR Russell 2000 US Small Cap€R2US | $5B | 0.00% |
SPDR Russell 2000 US Small Cap£R2SC | $5B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.